Gastric Cancer: Effect of poblinib combined with yewol and quordzumab in the treatment of patients with HER2-positive advanced gastric cancer.

!---- Pozitinib (HM781-36B) is an irreversible panHER tyrosine kinase inhibitor that targets EGFR, HER2 and HER4.this prospective, multi-center, open-label, Phase I/II study identified the maximum tolerable dose (MTD) and evaluated the safety and efficacy of pozidinis combined yewol and quordlome in patients with HER2-positive advanced gastric cancer (GC).her2-positive GC patients receive first-line chemotherapy, oral pozitinib (8 mg or 12 mg), once a day for 14 days, followed by a 7-day suspension.yew alcohol (175 mg/m2 infusion) and quercetal monoidat (8 mg/kg load dose, then 6 mg/kg infusion) performed simultaneously with poziotinib, once every 3 weeks and 1 day.results showed that in Phase I, 12 patients were enrolled in the group (7 at the dose level 1,5 at the dose level 2).1 patient who received 8 mg of botriatin and 2 patients receiving 12 mg of bosoteninini developed dose-restricted toxicity (DLTs); the most common adverse eventsare diarrhea, rash, stomatitis, itching and loss of appetite.MTD in Pozitinib was identified as 8mg/day, which was used in The Phase II section, which included 32 patients.2 patients (6.3%) had a complete response and 5 (15.6%) had a partial response (objective response rate of 21.9%).median progression-free lifetime and total lifetime were 13.0 weeks (95% CI 9.8-21.9) and 29.5 weeks (95% CI 17.9-59.2), respectively.in general, the results showed that pozidinib combined with yewol and quercetal monotol mTD were 8mg/day.this combination has a promising anti-tumor effect on HER2-positive GC patients who have been treated in the past, and the toxicity is controllable..